




CAPWHN Speaker Series Virtual Event


AGENDA

November 3rd 2022


TIMES ARE IN EST

Time	Session
12:00 PM	<p>Welcome & Opening Remarks</p> <p>Dr. Catherine Sheffer CAPWHN President</p>
12:10 PM	<p>Quantitative Blood Loss - How Alberta is Reducing the Risk.</p> <p>Presenter: Dr. Stephanie Cooper</p> <p>Learning Objectives:</p> <ul style="list-style-type: none">• To highlight the value of a standardized approach towards the management of PPH, including protocols and checklist and stage-based definitions and management for PPH• To promote objective quantification of blood loss in obstetrical hemorrhage• Discuss how nationally Canada can reduce PPH <p>This session is made possible by an educational grant from Ferring Pharmaceuticals</p> 



Time	Session
1:15 PM	<p>Pediatric Atopic Dermatitis (AD): Latest Insights and Current Guidelines on Emollient Therapy</p> <p>Presenter: Menas G. Kizoulis, Skin Health Scientific Engagement Director, Johnson & Johnson</p> <p>Learning Objectives</p> <ul style="list-style-type: none"> • Review pediatric skin health fundamentals and how it differs from adult skin health • Explore current AD guidelines and best practices for the prevention and maintenance of AD • Discuss the basic and clinical research supporting the use multi-benefits of oat therapy in pediatric populations <p>This session is made possible by an educational grant from Johnson & Johnson</p> <p style="text-align: center;"><i>Johnson & Johnson</i></p>
2:15 PM	<p>BREAK</p>
2:30 PM	<p>Preterm Prelabour Rupture of Membranes (PPROM): New Cutting Edge Information</p> <p>Presenter: Dr. Stefania Ronzoni, MD PhD MFM Specialist, Sunnybrook Health Sciences Center Associate Professor, University of Toronto, ON Canada</p> <p>Learning Objectives</p> <ul style="list-style-type: none"> • To review the just released recommendations from SOGC • To discuss the tests to confirm PPRM • To outline nursing assessment of individuals with PPRM • To describe treatment regimens for PPRM • To consider outcomes of PPRM in different clinical scenarios <p>This session is made possible by an educational grant from Obix perinatal data system</p> <p style="text-align: center;">  <small>BY CLINICAL COMPUTER SYSTEMS INC.</small> </p>



Time	Session
3:30 PM	<p>Contraceptive Counselling for Long-Acting Reversible contraceptives (LARCs): Intersecting choice with clinical, medical & practical considerations</p> <p>Speaker: Dr. Dustin Costescu</p> <p>Learning Objectives:</p> <ul style="list-style-type: none"> • Discuss how to identify patients who might likely benefit from hormonal based LARCs as an option • Assess how to organize and prepare your clinical space for the administration of hormonal based LARCS • Review practical considerations on how to manage side effects of hormonal based LARC <p>This session is made possible by an educational grant from Organon</p> 
4:30 PM	BREAK
4:45 PM	<p>CAPWHN AGM (CAPWHN members only) – Registration to the Speaker Series is NOT necessary but a separate Pre-registration is required to attend:</p> <p>https://us06web.zoom.us/meeting/register/tZMpde6rqDMpGdCcVGvXd0Xvpi_NRJUZdfYV</p>



SPONSOR ADVERTISEMENTS



Not shown to actual size.
Actual implant is 4 cm in length.

THE FIRST AND ONLY

SINGLE-ROD, PROGESTIN-ONLY LARC THAT'S IMPLANTED IN THE ARM*^{1,2}

NEXPLANON[®] IS USED FOR UP TO 3 YEARS OF PREGNANCY PREVENTION.¹

NEXPLANON[®] (etonogestrel extended release subdermal implant) is indicated for the prevention of pregnancy for up to 3 years.

Consult the Product Monograph at https://www.organon.com/canada-en/wp-content/uploads/sites/5/2021/05/NEXPLANON-PM_E.pdf for important information about:

- Contraindications in: known or suspected pregnancy; current or past history of thrombosis or thromboembolic disorders; liver tumours, benign or malignant, or active liver disease; undiagnosed abnormal genital bleeding; known or suspected breast cancer, personal history of breast cancer, or other progestin-sensitive cancer, now or in the past
- The most serious warnings and precautions regarding: insertion/removal by Healthcare Professionals, immediate action if not palpable, and protection against sexually transmitted infections
- Other relevant warnings and precautions regarding: complications of insertion and removal, changes in the menstrual bleeding pattern, *in situ* broken or bent implant – the broken implant may move from the insertion site, medical examination/consultation prior to the initiation or reinstatement of NEXPLANON[®], concomitant medications, carcinoma of the breast and reproductive organs, elevated blood pressure, thrombotic and other vascular events, carbohydrate and lipid metabolic effects, weight gain, fluid retention, ectopic pregnancy, ovarian cysts, liver disease, gallbladder disease, laboratory parameters, ophthalmologic considerations in contact lens wearers, peri-operative considerations, depressed mood, return to ovulation, chloasma, breast-feeding, and other conditions reported during pregnancy and during sex steroid use not otherwise described
- Conditions of clinical use, adverse reactions, drug interactions, and dosing information

The Product Monograph is also available through our medical department. Call us at 1-844-820-5468.

* Comparative clinical significance is unknown.
LARC=long-acting reversible contraceptive

References: **1.** NEXPLANON[®] Product Monograph. Organon Canada Inc. April 13, 2021. **2.** Data on file.

 **ORGANON**

